{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:11:36Z","timestamp":1746850296566,"version":"3.40.5"},"reference-count":166,"publisher":"Elsevier","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.030","type":"book-chapter","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T19:59:24Z","timestamp":1746820764000},"source":"Crossref","is-referenced-by-count":0,"title":["Blood and digital biomarkers in MG"],"prefix":"10.1016","author":[{"given":"Amol K.","family":"Bhandage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2025.04.030_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrm3611","article-title":"Diversifying microRNAf: Sequence and function","volume":"14","author":"Ameres","year":"2013","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/bs.irn.2025.04.030_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10072-017-3026-2","article-title":"Diagnostics of myasthenic syndromes: Detection of anti-AChR and anti-MuSK antibodies","volume":"38","author":"Andreetta","year":"2017","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5507\/bp.2019.009","article-title":"Upregulation of MiR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of il-17 and increased serum levels of IL-10","volume":"164","author":"Ao","year":"2020","journal-title":"Biomedical Papers"},{"key":"10.1016\/bs.irn.2025.04.030_bib4","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurology: Neuroimmunology and NeuroInflammation"},{"key":"10.1016\/bs.irn.2025.04.030_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0303-8467(93)90103-N","article-title":"Soluble terminal complement components in human myasthenia gravis","author":"Barohn","year":"1993","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/bs.irn.2025.04.030_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: Correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040740","article-title":"Towards personalized medicine in myasthenia gravis: Role of circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p","volume":"11","author":"Beretta","year":"2022","journal-title":"Cells"},{"key":"10.1016\/bs.irn.2025.04.030_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/948723","article-title":"The protective role of HLA-DRB1(\u204e)13 in autoimmune diseases","volume":"2015","author":"Bettencourt","year":"2015","journal-title":"Journal of Immunology Research"},{"key":"10.1016\/bs.irn.2025.04.030_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110564","article-title":"Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls","volume":"27","author":"Bhandage","year":"2024","journal-title":"iScience"},{"key":"10.1016\/bs.irn.2025.04.030_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11306-019-1625-z","article-title":"Metabolomic profile overlap in prototypical autoimmune humoral disease: A comparison of myasthenia gravis and rheumatoid arthritis","volume":"16","author":"Blackmore","year":"2020","journal-title":"Metabolomics"},{"key":"10.1016\/bs.irn.2025.04.030_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11306-019-1571-9","article-title":"Beyond the antibodies: Serum metabolomic profiling of myasthenia gravis","volume":"15","author":"Blackmore","year":"2019","journal-title":"Metabolomics"},{"key":"10.1016\/bs.irn.2025.04.030_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00142","article-title":"miR-146a in myasthenia gravis thymus bridges innate immunity with autoimmunity and is linked to therapeutic effects of corticosteroids","volume":"11","author":"Bortone","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2024.04.020","article-title":"Eculizumab in adolescent patients with refractory generalized myasthenia gravis: A phase 3, open-label, multicenter study","volume":"156","author":"Brandsema","year":"2024","journal-title":"Pediatric Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jocn.2019.08.079","article-title":"Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort","volume":"69","author":"Cai","year":"2019","journal-title":"Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia"},{"key":"10.1016\/bs.irn.2025.04.030_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666046","article-title":"A stable cell line expressing clustered AChR: A novel cell-based assay for anti-AChR antibody detection in myasthenia gravis","volume":"12","author":"Cai","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population","volume":"343","author":"Chang","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2016.09.003","article-title":"The role of microRNAs in the pathogenesis of autoimmune diseases","volume":"15","author":"Chen","year":"2016","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/bs.irn.2025.04.030_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1","volume":"33","author":"Cheng","year":"2013","journal-title":"Journal of Clinical Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib21","article-title":"Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study","volume":"119","author":"Chia","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2025.04.030_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","article-title":"The HLA system: Genetics, immunology, clinical testing, and clinical implications","volume":"48","author":"Choo","year":"2007","journal-title":"Yonsei Medical Journal"},{"key":"10.1016\/bs.irn.2025.04.030_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/ecn.2015.0367","article-title":"Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients","volume":"26","author":"Chunjie","year":"2015","journal-title":"European Cytokine Network"},{"key":"10.1016\/bs.irn.2025.04.030_bib24","article-title":"Functional signature of LRP4 antibodies in myasthenia gravis","volume":"11","author":"Chuquisana","year":"2024","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/bs.irn.2025.04.030_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and consequences of miR-150-5p dysregulation in myasthenia gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: A decade of discovery and diseases","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.irn.2025.04.030_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-313X.2010.00979.x","article-title":"Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States","volume":"38","author":"Deitiker","year":"2011","journal-title":"International Journal of Immunogenetics"},{"key":"10.1016\/bs.irn.2025.04.030_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/bs.irn.2025.04.030_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: An update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib31","year":"2016"},{"key":"10.1016\/bs.irn.2025.04.030_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humimm.2003.10.003","article-title":"HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis","volume":"65","author":"Fernandez-Mestre","year":"2004","journal-title":"Human Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib33","doi-asserted-by":"crossref","DOI":"10.2196\/43387","article-title":"A digital telehealth system to compute the myasthenia gravis core examination metrics","volume":"2","author":"Garbey","year":"2023","journal-title":"JMIR Neurotechnology"},{"key":"10.1016\/bs.irn.2025.04.030_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.gene.6364041","article-title":"Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis","volume":"5","author":"Giraud","year":"2004","journal-title":"Genes and Immunity"},{"key":"10.1016\/bs.irn.2025.04.030_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.030_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/mus.27260","article-title":"Telemedicine visits in myasthenia gravis: Expert guidance and the myasthenia gravis core exam (MG-CE)","volume":"64","author":"Guidon","year":"2021","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib40","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurology: Neuroimmunology and NeuroInflammation"},{"key":"10.1016\/bs.irn.2025.04.030_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1744-313X.2009.00843.x","article-title":"HLA class I and class II polymorphisms in Saudi patients with myasthenia gravis","volume":"36","author":"Hajeer","year":"2009","journal-title":"International Journal of Immunogenetics"},{"key":"10.1016\/bs.irn.2025.04.030_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/bs.irn.2025.04.030_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.26169","article-title":"Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease","volume":"90","author":"Handunnetthi","year":"2021","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106130","article-title":"Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis","volume":"80","author":"Hu","year":"2020","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.irn.2025.04.030_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-022-00501-8","article-title":"Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis","volume":"23","author":"Huan","year":"2022","journal-title":"BMC Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.28177","article-title":"Short-term changes in serum miRNA levels and patient-reported clinical outcomes in myasthenia gravis","volume":"70","author":"Huang","year":"2024","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156485","article-title":"Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse","volume":"175","author":"Huang","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/bs.irn.2025.04.030_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/mus.28227","article-title":"Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis","author":"Huang","year":"2024","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","author":"Huda","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","article-title":"Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity","volume":"291","author":"Huijbers","year":"2016","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061360","article-title":"Complement activation profile in myasthenia gravis patients: Perspectives for tailoring anti-complement therapy","volume":"10","author":"Iacomino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/bs.irn.2025.04.030_bib55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/cts.13529","article-title":"Digital health technology derived measures: Biomarkers or clinical outcome assessments?","volume":"16","author":"Izmailova","year":"2023","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/bs.irn.2025.04.030_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jneuroim.2015.09.010","article-title":"Serum interleukin-27 expression in patients with myasthenia gravis","volume":"288","author":"Jeong","year":"2015","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2012.07.003","article-title":"Altered let-7 expression in myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells","volume":"14","author":"Jiang","year":"2012","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.irn.2025.04.030_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: The future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.irn.2025.04.030_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: The future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.irn.2025.04.030_bib61","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell\u2013activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib62","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10072-015-2236-8","article-title":"Both binding and blocking antibodies correlate with disease severity in myasthenia gravis","volume":"36","author":"Kang","year":"2015","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00043","article-title":"Regulatory B cells in seropositive myasthenia gravis versus healthy controls","volume":"8","author":"Karim","year":"2017","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2017.03.003","article-title":"CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients","volume":"179","author":"Kohler","year":"2017","journal-title":"Clinical Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib65","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2025.04.030_bib66","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cbin.11676","article-title":"Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133\/PAX7","volume":"45","author":"Lai","year":"2021","journal-title":"Cell Biology International"},{"key":"10.1016\/bs.irn.2025.04.030_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: Autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib68","article-title":"AI-powered telemedicine for automatic scoring of neuromuscular examinations","volume":"11","author":"Lesport","year":"2024","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/bs.irn.2025.04.030_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10072-013-1460-3","article-title":"Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis","volume":"35","author":"Li","year":"2014","journal-title":"Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib70","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1007\/s12035-016-0024-y","article-title":"Gene polymorphisms for both auto-antigen and immune-modulating proteins are associated with the susceptibility of autoimmune myasthenia gravis","volume":"54","author":"Li","year":"2017","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib71","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577279","article-title":"Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis","volume":"345","author":"Li","year":"2020","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm-19-363","article-title":"Serological diagnosis of myasthenia gravis and its clinical significance","volume":"11","author":"Li","year":"2023","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/bs.irn.2025.04.030_bib74","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10072-019-04213-7","article-title":"The associations of HLA-DRB1 gene polymorphisms with late-onset myasthenia gravis: A meta-analysis","volume":"41","author":"Ling","year":"2020","journal-title":"Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib75","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clim.2015.12.009","article-title":"MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10","volume":"164","author":"Liu","year":"2016","journal-title":"Clinical Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib76","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4049\/jimmunol.1901176","article-title":"IL-37 Represses the autoimmunity in myasthenia gravis via directly targeting follicular Th and B cells","volume":"204","author":"Liu","year":"2020","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib77","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s11306-011-0364-6","article-title":"Serum metabolomics for the diagnosis and classification of myasthenia gravis","volume":"8","author":"Lu","year":"2012","journal-title":"Metabolomics"},{"key":"10.1016\/bs.irn.2025.04.030_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","article-title":"Altered expression of miR-146a in myasthenia gravis","volume":"555","author":"Lu","year":"2013","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2025.04.030_bib79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10616-021-00472-5","article-title":"MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells","volume":"73","author":"Lu","year":"2021","journal-title":"Cytotechnology"},{"key":"10.1016\/bs.irn.2025.04.030_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/bmjhci-2023-100914","article-title":"Definitions of digital biomarkers: A systematic mapping of the biomedical literature","volume":"31","author":"Macias Alonso","year":"2024","journal-title":"BMJ Health & Care Informatics"},{"key":"10.1016\/bs.irn.2025.04.030_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135378","article-title":"Flow cytofluorimetric analysis of anti-LRP4 (LDL receptor-related protein 4) autoantibodies in italian patients with myasthenia gravis","volume":"10","author":"Marino","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.04.030_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577850","article-title":"The clinical need for clustered AChR cell-based assay testing of seronegative MG","volume":"367","author":"Masi","year":"2022","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib84","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2025.04.030_bib85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib86","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis","volume":"108","author":"Meraouna","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.irn.2025.04.030_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120084","article-title":"Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis","volume":"432","author":"Mirian","year":"2022","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13317-019-0124-6","article-title":"Associations between HLA and autoimmune neurological diseases with autoantibodies","volume":"11","author":"Muniz-Castrillo","year":"2020","journal-title":"Auto- Immunity Highlights"},{"key":"10.1016\/bs.irn.2025.04.030_bib89","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00415-011-6036-7","article-title":"Elevated serum level of interleukin-32\u03b1 in the patients with myasthenia gravis","volume":"258","author":"Na","year":"2011","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1121","article-title":"Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases: A comprehensive review","volume":"11","author":"Nag","year":"2023","journal-title":"Immunity, Inflammation and Disease"},{"key":"10.1016\/bs.irn.2025.04.030_bib91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib92","unstructured":"National Institutes of Health (NIH), (n.d.). Toolkit for patient-focused therapy development-biomarkers. https:\/\/toolkit.ncats.nih.gov\/module\/discovery\/developing-translational-research-tools\/biomarkers\/."},{"key":"10.1016\/bs.irn.2025.04.030_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091927","article-title":"Analysis of serum miRNA profiles of myasthenia gravis patients","volume":"9","author":"Nogales-Gadea","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.04.030_bib94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.26590","article-title":"Central role of macrophages and nucleic acid release in myasthenia gravis thymus","volume":"93","author":"Payet","year":"2023","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071218","article-title":"Myasthenia gravis: An acquired interferonopathy?","volume":"11","author":"Payet","year":"2022","journal-title":"Cells"},{"key":"10.1016\/bs.irn.2025.04.030_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2457","article-title":"LncRNA GAS5 positively regulates IL-10 expression in patients with generalized myasthenia gravis","volume":"12","author":"Peng","year":"2022","journal-title":"Brain and Behavior"},{"key":"10.1016\/bs.irn.2025.04.030_bib97","unstructured":"Peng, Y.,\u00a0et al. (2024). Journal of Translational Medicine, 22, BioMed Central Ltd."},{"key":"10.1016\/bs.irn.2025.04.030_bib98","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","article-title":"Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis","volume":"292","author":"Punga","year":"2016","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating mi RNA s in myasthenia gravis: miR\u2010150\u20105p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib101","doi-asserted-by":"crossref","unstructured":"Roberts,\u00a0T. C. (2014). Molecular Therapy Nucleic Acids, 3, Nature Publishing Group.","DOI":"10.1038\/mtna.2014.40"},{"key":"10.1016\/bs.irn.2025.04.030_bib102","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib103","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodriguez Cruz","year":"2015","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib104","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi","year":"2000","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib106","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(00)00394-5","article-title":"Complement activation by titin and ryanodine receptorautoantibodies in myasthenia gravis. A study of IgG subclasses and clinicalcorrelations","volume":"111","author":"Romi","year":"2000","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib107","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/acn3.51823","article-title":"Assessing facial weakness in myasthenia gravis with facial recognition software and deep learning","volume":"10","author":"Ruiter","year":"2023","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib108","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2018.10.003","article-title":"Circulating microRNA plasma profile in MuSK+ myasthenia gravis","volume":"325","author":"Sabre","year":"2018","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib109","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib111","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib112","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1007\/s10072-022-06102-y","article-title":"HLA-DQB1\u204e05:02, \u204e05:03, and \u204e03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort","volume":"43","author":"Salvado","year":"2022","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00015","article-title":"Cytokine targeting by miRNAs in autoimmune diseases","volume":"10","author":"Salvi","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib114","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.nmd.2017.04.002","article-title":"HLA and age of onset in myasthenia gravis","volume":"27","author":"Santos","year":"2017","journal-title":"Neuromuscular Disorders: NMD"},{"key":"10.1016\/bs.irn.2025.04.030_bib115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mus.26507","article-title":"Refractory myasthenia gravis: Characteristics of a portuguese cohort","volume":"60","author":"Santos","year":"2019","journal-title":"Muscle &\u00a0Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102635","article-title":"Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment","volume":"9","author":"Sengupta","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.04.030_bib117","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: Biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/bs.irn.2025.04.030_bib118","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.12659\/MSM.893458","article-title":"miR-15b is downregulated in myasthenia gravis patients and directly regulates the expression of interleukin-15 (IL-15) in experimental myasthenia gravis mice","volume":"21","author":"Shi","year":"2015","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"key":"10.1016\/bs.irn.2025.04.030_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287654","article-title":"Serum metabolomics of treatment response in myasthenia gravis","volume":"18","author":"Sikorski","year":"2023","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.04.030_bib120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/jtd.2016.03.03","article-title":"Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma","volume":"8","author":"Song","year":"2016","journal-title":"Journal of Thoracic Disease"},{"key":"10.1016\/bs.irn.2025.04.030_bib121","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis","volume":"30","author":"Stascheit","year":"2023","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib122","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2023.12293","article-title":"MicroRNA\u2011155\u20115p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis","volume":"27","author":"Sun","year":"2023","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/bs.irn.2025.04.030_bib123","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jneuroim.2005.10.001","article-title":"Altered expression of Th1-type chemokine receptor CXCR3 on CD4+ T cells in myasthenia gravis patients","volume":"172","author":"Suzuki","year":"2006","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib124","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies","volume":"21","author":"Suzuki","year":"2014","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib125","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/740583","article-title":"Three types of striational antibodies in myasthenia gravis","volume":"2011","author":"Suzuki","year":"2011","journal-title":"Autoimmune Diseases"},{"key":"10.1016\/bs.irn.2025.04.030_bib126","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4+CD25highCD127low\/- T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clinical Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2025.04.030_bib129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaut.2005.09.010","article-title":"Genetics of autoimmune myasthenia gravis: The multifaceted contribution of the HLA complex","volume":"25","author":"Vandiedonck","year":"2005","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.030_bib131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaut.2017.10.002","article-title":"Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis","volume":"88","author":"Varade","year":"2018","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.030_bib132","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.humimm.2007.05.009","article-title":"Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis","volume":"68","author":"Viken","year":"2007","journal-title":"Human immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib133","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib134","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in myasthenia gravis: A review of the current evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/bs.irn.2025.04.030_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112275","article-title":"Increased serum interleukin-41 correlates with disease severity in myasthenia gravis","volume":"134","author":"Wang","year":"2024","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.irn.2025.04.030_bib136","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib137","doi-asserted-by":"crossref","unstructured":"Wang, L., & Zhang,\u00a0L. (2020). Frontiers in Neuroscience, 14, Frontiers Media S.A.","DOI":"10.3389\/fnins.2020.00507"},{"key":"10.1016\/bs.irn.2025.04.030_bib138","article-title":"Altered serum levels of cytokines in patients with myasthenia gravis","volume":"10","author":"Wei","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/bs.irn.2025.04.030_bib139","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.049","article-title":"Imbalance of circulating CD4+CXCR5+FOXP3+ Tfr-like cells and CD4+CXCR5+FOXP3\u2212 Tfh-like cells in myasthenia gravis","volume":"630","author":"Wen","year":"2016","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2025.04.030_bib140","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/bs.irn.2025.04.030_bib141","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of myasthenia gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/bs.irn.2025.04.030_bib142","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9595718","article-title":"MIR-20b inhibits T cell proliferation and activation via NFAT signaling pathway in thymoma-associated myasthenia gravis","volume":"2016","author":"Xin","year":"2016","journal-title":"BioMed Research International"},{"key":"10.1016\/bs.irn.2025.04.030_bib143","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of treg-associated molecules on CD4+CD25+Treg cells in myasthenia gravis and effects of Immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"Journal of Clinical Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib144","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mus.26785","article-title":"Plasma exosomal miR-106a-5p expression in myasthenia gravis","volume":"61","author":"Xu","year":"2020","journal-title":"Muscle and Nerve"},{"key":"10.1016\/bs.irn.2025.04.030_bib145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12026-020-09164-2","article-title":"IL-21 enhances STAT3\/Blimp-1 signaling pathway in B cells and contributes to plasma cell differentiation in newly diagnosed patients with myasthenia gravis","author":"Xu","year":"2021","journal-title":"Immunologic Research"},{"key":"10.1016\/bs.irn.2025.04.030_bib146","article-title":"Intrathymic plasmablasts are affected in patients with myasthenia gravis with active disease","volume":"8","author":"Yamamoto","year":"2021","journal-title":"Neurology: Neuroimmunology and NeuroInflammation"},{"key":"10.1016\/bs.irn.2025.04.030_bib147","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10072-017-3009-3","article-title":"High frequencies of circulating Tfh-Th17 cells in myasthenia gravis patients","volume":"38","author":"Yang","year":"2017","journal-title":"Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.030_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578205","article-title":"Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies","volume":"384","author":"Yasuda","year":"2023","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib149","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00034","article-title":"B10 cell frequencies and suppressive capacity in myasthenia gravis are associated with disease severity","volume":"8","author":"Yi","year":"2017","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib151","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jocn.2020.11.017","article-title":"Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab","volume":"86","author":"Yi","year":"2021","journal-title":"Journal of Clinical Neuroscience"},{"key":"10.1016\/bs.irn.2025.04.030_bib152","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/08916934.2014.992517","article-title":"B cells produce less IL-10, IL-6 and TNF-\u03b1 in myasthenia gravis","volume":"48","author":"Yilmaz","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.030_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123546","article-title":"Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK","volume":"10","author":"Yilmaz","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.04.030_bib154","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/acn3.645","article-title":"Regulatory B cells in myasthenia gravis are differentially affected by therapies","volume":"5","author":"Yilmaz","year":"2018","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib155","first-page":"99","article-title":"Association of HLA-DQA1\u204e0101\/2 and DQB1\u204e0502 with myasthenia gravis in southern Iranian patients","volume":"6","author":"Yousefipour","year":"2009","journal-title":"Iranian Journal of Immunology: IJI"},{"key":"10.1016\/bs.irn.2025.04.030_bib156","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib157","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11481-015-9638-5","article-title":"TIPE2 play a negative role in TLR4-mediated autoimmune T helper 17 cell responses in patients with myasthenia gravis","volume":"10","author":"Zhang","year":"2015","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"10.1016\/bs.irn.2025.04.030_bib158","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib159","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic Tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: Central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/bs.irn.2025.04.030_bib160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10238-015-0358-1","article-title":"Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis","volume":"16","author":"Zhang","year":"2016","journal-title":"Clinical and Experimental Medicine"},{"key":"10.1016\/bs.irn.2025.04.030_bib161","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clineuro.2017.04.012","article-title":"Individual participant data analysis comparing acute stroke patients with anterior versus posterior circulation dissections","author":"Zhang","year":"2017","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/bs.irn.2025.04.030_bib162","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-020-01885-z","article-title":"Increased serum IL-36\u03b3levels are associated with disease severity in myasthenia gravis patients","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib163","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12883-021-02439-7","article-title":"Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: A single-centre retrospective cohort study","volume":"21","author":"Zhao","year":"2021","journal-title":"BMC Neurology"},{"key":"10.1016\/bs.irn.2025.04.030_bib164","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/sji.12057","article-title":"Expression of interleukin-22 in myasthenia gravis","volume":"78","author":"Zheng","year":"2013","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.030_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102349","article-title":"HLA in myasthenia gravis: From superficial correlation to underlying mechanism","volume":"18","author":"Zhong","year":"2019","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/bs.irn.2025.04.030_bib166","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"Journal of Autoimmunity"}],"container-title":["International Review of Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T20:00:01Z","timestamp":1746820801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":166,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.030","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}